CD274 and non-small cell lung carcinoma: Nivolumab and Pembrolizumab, which can target programmed cell death 1 (PD-1, PDCD1), and Durvalumab, anti-programmed cell death-ligand 1 (CD274, PD-L1) inhibitors that are all approved for the treatment of some NSCLC patients with disease progression after targeted therapy [12].